Iranian Pharmaceutical Industry Opportunities in Iraq
-
Ahmed Hayder Mohsin Al Iami
,
Saman Zartab
,
Mona Jaberidoost
,
Alireza Yektadoost
,
Shekoufeh Nikfar
,
Abbas Kebriaeezadeh
Abstract
Background: The socioeconomic and political situation of Iraq has provided a wide and open market. Because of the weak pharmaceutical industry and war, Iraq has a huge demand for pharmaceutical and medical services; this country is a reliable market in the pharmaceuticals trade. Iran has a long border and good political relationship with Iraq, besides a great pharmaceutical industry. However, because of wrong policies and the lack of competition power, Iran failed to significantly impact Iraq’s pharmaceutical market. We aimed to analyze Iraq’s pharmaceutical trade market, address the factors affecting pharmaceuticals trade between Iran and Iraq, and provide suggestions to promote Iran in Iraq’s pharmaceutical market.Methods: Two questionnaires were designed based on the information obtained from articles related to the pharmaceutical industry. Questionnaires were completed by 10 Iraqi pharmaceutical experts. Then, we analyzed the obtained results by Simple Additive Weight (SAW) method. Based on the results of the analysis, we attempted to find the most important factors affecting Iran’s role in Iraq pharmaceutical market and clarify its situation.Results: The achieved results revealed 10 factors out of the 45 factors were more important and the majority of them were related to quality and marketing strategy.Conclusion: The study has suggested that quality and marketing power are the most important factors that affect the Iran-Iraq pharmaceutical business.
[1] Woods JE, Blake GH, Kennedy H, Khadduri M, Richard L. Iraq [internet]. 2018 [Accessed 2018 Mar 4]. Available from: www.britannica. com/place/Iraq
[2] Ministry of Health and Medical Education. [Annual report (Persian)]. Tehran: Ministry of Health and Medical Education; 2016.
[3] Al-Jumaili AA, Hussain SA, Sorofman B. Pharmacy in Iraq: History, current status, and future directions. Am J Health Syst Pharm. 2013; 70(4):368-72. [DOI:10.2146/ajhp120415] [PMID]
[4] Ministry of Finance. Final Iraq budget 2016. The federal general budget law of the Republic of Iraq for Fiscal Year 2016. Baghdad: Ministry of Finance; 2015.
[5] Al-Shariah Al-Iraqi Rule. [Higher judicial council, foreign investment law (Arabic)] [Internet]. 2018 [Accessed 2018 February 17]. Available from: http://www.iraqld.iq/LoadLawBook. aspx?page=1&SC=&BookID=28405
[6] Tadlock RD. Occupation law and foreign investment in Iraq: How an outdated doctrine has become an obstacle to occupied populations. USFL Rev. 2004; 39(1):227-60.
[7] Iraqi Ministry of Higher Education and Scientific Research. [Pharmacy schools statistics (Arabic)] [Internet]. 2017 [Accessed 2017 Nov 11]. Available from: www.mohesr.gov.iq
[8] Syndicate of Iraqi Pharmacists. [Pharmacy schools statistics (Arabic)] [Internet]. 2017 [Accessed 2017 June 14]. Available from: http://www.iraqipharm.com
[9] Republic of Iraq, Ministry of Health, Environment the State Co. for Marketing Drugs and Medical Appliances. About us [Internet]. 2016 [Updated 2016 April 24]. Available from: http://kimadia.iq/en/cms/ about
[10] Irqai League for Medicine Producer N-G-O. [Companies and factories (Arabic)] [Internet]. 2017 [Updated 2017 March 2]. Available from: http://iraqdma.com/?page_id=96
[11] Directoroate of technichal affairs. Pharmaceutical factories statistics [Internet]. 2017 [Updated 2017 June 10]. Available from: http:// www.tecmoh.com/pharmacy.php
[12] World Bank. Annual report 2016. Washington, D.C.: The World bank; 2016.
[13] Cheraghali AM. Trends in Iran pharmaceutical market. Iran J Pharm Res. 2017; 16(1):1-7.
[14] Food and Drug Administration of the Islamic Republic of Iran. [Iranian Ministry of Health Annual Pharma Statistics (Persian)] [Internet]. 2017 [Updated 13 June 2017]. Available from: http://www. fda.gov.ir/item/3814
[15] Zaboli P, Hashemi-Meshkini A, Varmaghani M, Gholami H, Vazirian I, Zekri HS, et al. Pharmaceutical laws and regulations in Iran: An overview. J Res Pharm Pract. 2016; 5(3):155-61. [DOI:10.4103/2279042X.185709] [PMID] [PMCID]
[16] Kebriaeezadeh A, Koopaei NN, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the pharmaceutical market in Iran; 19972010; policy implications for developing countries. DARU J Pharm Sci. 2013; 21(1):52. [DOI:10.1186/2008-2231-21-52] [PMID] [PMCID]
[17] Yusefzadeh H, Rezapour A, Lotfi F, Azar FE, Nabilo B, Gorji HA, et al. A Study of comparative advantage and intra-industry trade in the pharmaceutical industry of Iran. Glob J Health Sci. 2015; 7(6):295307. [DOI:10.5539/gjhs.v7n6p295] [PMID] [PMCID]
[18] Cheraghali AM. Current status of biopharmaceuticals in Iran’s pharmaceutical market. Generics Biosimilars Initiat J. 2013; 2(1):2631. [DOI:10.5639/gabij.2013.0201.008]
[19] Seyedifar M, Nikfar S, Abdollahi-Asl A, Rasekh H, Ehsani A, Kebriaeezadeh A. An evaluation of policies and procedures of successful pharmaceutical exporters and the comparison of Iranian counterpart policy. J Pharmacoecon & Pharm Manage. 2015; 1(3/4):39-44.
[20] Tavakol M, Dennick R. Making sense of Cronbach’s alpha. Int J Med Educ. 2011; 2:53-5. [DOI:10.5116/ijme.4dfb.8dfd] [PMID] [PMCID]
[21] Jones PDA, Simons EN. Story of the saw: Published to mark the second centenary of the world’s oldest sawmakers, Spear & Jackson, limited, 1760-1960. Manchester: Newman Neame; 1961.
[22] Jaberidoost M, Olfat L, Hosseini A, Kebriaeezadeh A, Abdollahi M, Alaeddini M, et al. Pharmaceutical supply chain risk assessment in Iran using Analytic Hierarchy Process (AHP) and Simple Additive Weighting (SAW) methods. J Pharm Policy Pract. 2015; 8(1):9. [DOI:10.1186/s40545-015-0029-3] [PMID] [PMCID]
[23] Cheraghali AM. Impacts of international sanctions on Iranian pharmaceutical market. DARU J Pharm Sci. 2013; 21(1):64-7. [DOI:10.1186/2008-2231-21-64] [PMID] [PMCID]
[2] Ministry of Health and Medical Education. [Annual report (Persian)]. Tehran: Ministry of Health and Medical Education; 2016.
[3] Al-Jumaili AA, Hussain SA, Sorofman B. Pharmacy in Iraq: History, current status, and future directions. Am J Health Syst Pharm. 2013; 70(4):368-72. [DOI:10.2146/ajhp120415] [PMID]
[4] Ministry of Finance. Final Iraq budget 2016. The federal general budget law of the Republic of Iraq for Fiscal Year 2016. Baghdad: Ministry of Finance; 2015.
[5] Al-Shariah Al-Iraqi Rule. [Higher judicial council, foreign investment law (Arabic)] [Internet]. 2018 [Accessed 2018 February 17]. Available from: http://www.iraqld.iq/LoadLawBook. aspx?page=1&SC=&BookID=28405
[6] Tadlock RD. Occupation law and foreign investment in Iraq: How an outdated doctrine has become an obstacle to occupied populations. USFL Rev. 2004; 39(1):227-60.
[7] Iraqi Ministry of Higher Education and Scientific Research. [Pharmacy schools statistics (Arabic)] [Internet]. 2017 [Accessed 2017 Nov 11]. Available from: www.mohesr.gov.iq
[8] Syndicate of Iraqi Pharmacists. [Pharmacy schools statistics (Arabic)] [Internet]. 2017 [Accessed 2017 June 14]. Available from: http://www.iraqipharm.com
[9] Republic of Iraq, Ministry of Health, Environment the State Co. for Marketing Drugs and Medical Appliances. About us [Internet]. 2016 [Updated 2016 April 24]. Available from: http://kimadia.iq/en/cms/ about
[10] Irqai League for Medicine Producer N-G-O. [Companies and factories (Arabic)] [Internet]. 2017 [Updated 2017 March 2]. Available from: http://iraqdma.com/?page_id=96
[11] Directoroate of technichal affairs. Pharmaceutical factories statistics [Internet]. 2017 [Updated 2017 June 10]. Available from: http:// www.tecmoh.com/pharmacy.php
[12] World Bank. Annual report 2016. Washington, D.C.: The World bank; 2016.
[13] Cheraghali AM. Trends in Iran pharmaceutical market. Iran J Pharm Res. 2017; 16(1):1-7.
[14] Food and Drug Administration of the Islamic Republic of Iran. [Iranian Ministry of Health Annual Pharma Statistics (Persian)] [Internet]. 2017 [Updated 13 June 2017]. Available from: http://www. fda.gov.ir/item/3814
[15] Zaboli P, Hashemi-Meshkini A, Varmaghani M, Gholami H, Vazirian I, Zekri HS, et al. Pharmaceutical laws and regulations in Iran: An overview. J Res Pharm Pract. 2016; 5(3):155-61. [DOI:10.4103/2279042X.185709] [PMID] [PMCID]
[16] Kebriaeezadeh A, Koopaei NN, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the pharmaceutical market in Iran; 19972010; policy implications for developing countries. DARU J Pharm Sci. 2013; 21(1):52. [DOI:10.1186/2008-2231-21-52] [PMID] [PMCID]
[17] Yusefzadeh H, Rezapour A, Lotfi F, Azar FE, Nabilo B, Gorji HA, et al. A Study of comparative advantage and intra-industry trade in the pharmaceutical industry of Iran. Glob J Health Sci. 2015; 7(6):295307. [DOI:10.5539/gjhs.v7n6p295] [PMID] [PMCID]
[18] Cheraghali AM. Current status of biopharmaceuticals in Iran’s pharmaceutical market. Generics Biosimilars Initiat J. 2013; 2(1):2631. [DOI:10.5639/gabij.2013.0201.008]
[19] Seyedifar M, Nikfar S, Abdollahi-Asl A, Rasekh H, Ehsani A, Kebriaeezadeh A. An evaluation of policies and procedures of successful pharmaceutical exporters and the comparison of Iranian counterpart policy. J Pharmacoecon & Pharm Manage. 2015; 1(3/4):39-44.
[20] Tavakol M, Dennick R. Making sense of Cronbach’s alpha. Int J Med Educ. 2011; 2:53-5. [DOI:10.5116/ijme.4dfb.8dfd] [PMID] [PMCID]
[21] Jones PDA, Simons EN. Story of the saw: Published to mark the second centenary of the world’s oldest sawmakers, Spear & Jackson, limited, 1760-1960. Manchester: Newman Neame; 1961.
[22] Jaberidoost M, Olfat L, Hosseini A, Kebriaeezadeh A, Abdollahi M, Alaeddini M, et al. Pharmaceutical supply chain risk assessment in Iran using Analytic Hierarchy Process (AHP) and Simple Additive Weighting (SAW) methods. J Pharm Policy Pract. 2015; 8(1):9. [DOI:10.1186/s40545-015-0029-3] [PMID] [PMCID]
[23] Cheraghali AM. Impacts of international sanctions on Iranian pharmaceutical market. DARU J Pharm Sci. 2013; 21(1):64-7. [DOI:10.1186/2008-2231-21-64] [PMID] [PMCID]
| Files | ||
| Issue | Vol 3 No 3/4 (2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| SAW method Pharmaceutical industry Iran Iraq Export | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Mohsin Al Iami AH, Zartab S, Jaberidoost M, Yektadoost A, Nikfar S, Kebriaeezadeh A. Iranian Pharmaceutical Industry Opportunities in Iraq. JPPM. 2019;3(3/4):35-40.
